Updated results from MONALEESA‑2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC) - Hortobagyi, G N; Stemmer, S M; Burris, H A (J Clin Oncol, 2017)
(Suppl.): Abstr. 1038